Harmony Biosciences Drug Fails Fragile X Trial: What Went Wrong?
Harmony Biosciences’ experimental drug ZYN002 failed its Phase 3 trial for Fragile X syndrome, failing to meet its main goal for improving social avoidance primarily due to a high placebo response.